InsidersTradesSigma
Follow the Monopar Therapeutics Inc. share price and the full management transaction log of the company, a listed equity based in United States. Shares are quoted on the US market, under the authority of SEC (Form 4). Market capitalisation: €764.8m. The latest transaction was reported on 26 August 2026 (Notice of proposed sale (Form 144)). Among the most active insiders: Arthur Klausner. Every trade is openly available.
Analysts rate Monopar Therapeutics Inc. Strong Buy (bullish), based on 13 analysts. Average price target: US$126.31.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
5 of 5 declarations
Monopar Therapeutics Inc. 是一家生物制药公司，专注于开发罕见和难治性癌症的治疗方法。它采用创新方法来改善患者预后。